YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice
Jinshan Nan(Sichuan University), Shengyong Yang(Sichuan University), Huiping Shuai(Chinese University of Hong Kong), Hin Chu(Hong Kong Science and Technology Parks Corporation), YueShan Li(Sichuan University), Ronggang Ma(Sichuan University), Lanxin Du(Sichuan University), Chong Huang(Sichuan University), Shanshan Zhang(Sichuan University), Jiayu Sun(Sichuan University), Jingxin Qiao(Sichuan University), Lianzhao Du(University of Hong Kong), Lei Wang(University of Hong Kong), Wenyu Guo(University of Hong Kong), Xinyue Deng(Sichuan University), Jiaheng Hu(University of Hong Kong), Qiao Huang(Sichuan University), Yan Chen(Sichuan University), Chaemin Yoon(University of Hong Kong), Rui Zeng(Sichuan University), Lengjing Zhu(Sichuan University)
Cited by 0
Related Papers
Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study
|The Lancet Microbe|2020|838
Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the Pathogenesis of COVID-19
|Clinical Infectious Diseases|2020|713
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647